

Francesco Menzella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9072435/publications.pdf>

Version: 2024-02-01

99
papers

2,305
citations

201385

27
h-index

264894

42
g-index

105
all docs

105
docs citations

105
times ranked

2737
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden and risk factors for <i>Pseudomonas aeruginosa</i> community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018, 52, 1701190.	3.1	122
2	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019, 68, 1482-1493.	2.9	116
3	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	2.0	112
4	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1364-1376.	4.6	109
5	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 260-274.	5.2	102
6	Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. <i>World Allergy Organization Journal</i> , 2019, 12, 100007.	1.6	82
7	Tailored therapy for severe asthma. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 1.	0.6	57
8	One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836.	1.1	57
9	Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis. <i>Critical Care</i> , 2021, 25, 268.	2.5	56
10	Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163.	3.1	56
11	Effectiveness of noninvasive ventilation in COVID-19 related acute respiratory distress syndrome. <i>Clinical Respiratory Journal</i> , 2021, 15, 779-787.	0.6	52
12	<p>>A case of chronic eosinophilic pneumonia in a patient treated with dupilumab</p></p><p>>Therapeutics and Clinical Risk Management, 2019, Volume 15, 869-875.	0.9	49
13	Real-life Efficacy of Omalizumab After 9 Years of Follow-up. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 368.	1.1	47
14	Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. <i>BMC Pulmonary Medicine</i> , 2018, 18, 29.	0.8	47
15	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. <i>Critical Care</i> , 2020, 24, 589.	2.5	47
16	Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. <i>Journal of Asthma and Allergy</i> , 2015, 8, 105.	1.5	46
17	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. <i>Respiratory Medicine</i> , 2021, 176, 106261.	1.3	44
18	Long-term benefits of omalizumab in a patient with severe non-allergic asthma. <i>Allergy, Asthma and Clinical Immunology</i> , 2011, 7, 9.	0.9	40

#	ARTICLE	IF	CITATIONS
19	Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 902-905.	2.7	37
20	International prevalence and risk factors evaluation for drug-resistant <i>Streptococcus pneumoniae</i> pneumonia. <i>Journal of Infection</i> , 2019, 79, 300-311.	1.7	36
21	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2539-2541.	2.7	36
22	Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 150-161.	2.7	35
23	Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. <i>BMC Infectious Diseases</i> , 2018, 18, 677.	1.3	34
24	Quality standards for the management of bronchiectasis in Italy: a national audit. <i>European Respiratory Journal</i> , 2016, 48, 244-248.	3.1	33
25	COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	2.7	33
26	Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 87-95.	1.0	31
27	The clinical profile of benralizumab in the management of severe eosinophilic asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 534-548.	1.0	31
28	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020, 25, 543-551.	1.3	31
29	Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	1.6	30
30	Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 9.	0.6	27
31	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	1.0	26
32	Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 237-247.	1.5	23
33	Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. <i>ERJ Open Research</i> , 2018, 4, 00076-2018.	1.1	22
34	Severe refractory asthma: current treatment options and ongoing research. <i>Drugs in Context</i> , 2018, 7, 1-15.	1.0	22
35	Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for Omics Technology?. <i>BioMed Research International</i> , 2018, 2018, 1-15.	0.9	21
36	Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. <i>Vaccines</i> , 2021, 9, 420.	2.1	21

#	ARTICLE	IF	CITATIONS
37	Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 260-277.	1.1	20
38	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	20
39	Targeting eosinophils: severe asthma and beyond. <i>Drugs in Context</i> , 2019, 8, 212587.	1.0	20
40	Clinical usefulness of mepolizumab in severe eosinophilic asthma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 907.	0.9	19
41	<p>A Dangerous Consequence of the Recent Pandemic: Early Lung Fibrosis Following COVID-19 Pneumonia â€œ Case Reports</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 1039-1046.	0.9	18
42	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1513-1525.	1.3	18
43	Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1019-1026.	1.0	18
44	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	1.6	18
45	Combined immediate- and delayed-type hypersensitivity to metamizole. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 88-90.	2.7	17
46	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1460-1463.	2.7	16
47	Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101966.	1.1	16
48	A Budget Impact Analysis of Bronchial Thermoplasty for Severe Asthma in Clinical Practice. <i>Advances in Therapy</i> , 2014, 31, 751-761.	1.3	15
49	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 87-89.	1.1	15
50	<p>Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 301-313.	1.5	15
51	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	1.6	14
52	ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. <i>Respiratory Research</i> , 2022, 23, 36.	1.4	14
53	Pharmacological treatment of COVID-19: lights and shadows. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	13
54	Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 601-606.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Self-administration of omalizumab: why not? A literature review and expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 499-507.	1.4	12
56	Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 779.	0.6	12
57	A Survey of Clinical Features of Allergic Rhinitis in Adults. <i>Medical Science Monitor</i> , 2014, 20, 2151-2156.	0.5	12
58	A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM). <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1019-1031.	1.5	11
59	Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1213-1221.	0.9	10
60	Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661984135.	1.0	10
61	Real world effectiveness of benralizumab on respiratory function and asthma control. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 785.	0.6	10
62	Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach. <i>Journal of Personalized Medicine</i> , 2022, 12, 1096.	1.1	10
63	Heat-induced necrosis after bronchial thermoplasty: a new concern?. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 25.	0.9	9
64	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 419-424.	1.0	9
65	Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 149-161.	1.5	9
66	Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab. <i>Biomedicines</i> , 2021, 9, 348.	1.4	9
67	Towards precision medicine: The application of omics technologies in asthma management. <i>F1000Research</i> , 2018, 7, 423.	0.8	9
68	Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 505-515.	1.5	9
69	Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, 39.	0.9	9
70	Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. <i>Frontiers in Allergy</i> , 2022, 3, .	1.2	9
71	Integrated interventional bronchoscopy in the treatment of locally advanced non-small lung cancer with central Malignant airway Obstructions: a multicentric Retrospective study (EVERMORE). <i>Lung Cancer</i> , 2020, 148, 40-47.	0.9	8
72	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 163-172.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1489-1493.	0.9	6
74	Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 32.	0.6	6
75	Use of narrative medicine to identify key factors for effective doctor-patient relationships in severe asthma. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 26.	0.6	6
76	Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports. <i>Respiratory Medicine Case Reports</i> , 2020, 29, 100967.	0.2	6
77	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101874.	1.1	5
78	Pleural mesothelioma: When echo-endoscopy (EUS-EBUS-FNA) leads to diagnosis in a minimally invasive way. <i>Thoracic Cancer</i> , 2021, 12, 981-984.	0.8	5
79	May 2020: Is It Always COVID-19 No Matter What?. <i>International Medical Case Reports Journal</i> , 2020, Volume 13, 563-567.	0.3	5
80	Towards precision medicine: The application of omics technologies in asthma management. <i>F1000Research</i> , 2018, 7, 423.	0.8	4
81	Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONICE). <i>Clinical and Translational Allergy</i> , 2022, 12, e12143.	1.4	4
82	Severe asthma management in the era of biologics: insights of the Italian Registry on Severe Asthma (IRSA). <i>European Annals of Allergy and Clinical Immunology</i> , 2021, 53, 103.	0.4	3
83	The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 787.	0.6	3
84	COVID-19: general overview, pharmacological options and ventilatory support strategies. <i>Multidisciplinary Respiratory Medicine</i> , 2020, 15, 708.	0.6	2
85	Clinical Audit on Diagnostic Accuracy and Management of Respiratory Failure in COPD. <i>Respiratory Care</i> , 2012, 57, 2067-2073.	0.8	2
86	The role of systemic corticosteroids in severe asthma and new evidence in their management and tapering. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1283-1299.	1.3	2
87	Living with severe asthma year 2016. , 2017, , .		1
88	Severe asthma: one disease many definitions. , 2019, , .		1
89	Narrative medicine to evaluate the relationship between clinicians and patients living with severe asthma. , 2017, , .		1
90	Neurologist's contribution to the diagnosis of sine materia respiratory insufficiency: case report. <i>BMC Pulmonary Medicine</i> , 2012, 12, 42.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: from eligibility criteria to real practice. Journal of Allergy and Clinical Immunology, 2020, 145, AB17.	1.5	0
92	The effect of bronchial thermoplasty on nerve C-fibers and inflammatory cells in patients with severe asthma. , 2015, , .		0
93	Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report. Multidisciplinary Respiratory Medicine, 0, 13, .	0.6	0
94	Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE). , 2018, , .		0
95	Clinical and histologic effect of bronchial thermoplasty after 1 year. , 2018, , .		0
96	One year of mepolizumab in severe asthma in Italy: efficacy and safety. , 2019, , .		0
97	Switch Omalizumab â€œ Mepolizumab: real life experience. , 2019, , .		0
98	Bronchiectasis in Italy: data from the national registry IRIDE. , 2020, , .		0
99	Home-based treatment of biologics for asthma: who, what, where, when and why. Expert Review of Respiratory Medicine, 2022, , 1-10.	1.0	0